

**Supplementary Table 4: Patient information for Figure 4 A, B**

		CON	CD	UC
<b>Number</b>		2	2	3
<b>Age (Ø, range)</b>		31 (28-33))	55 (38-72)	22 (18-31)
<b>Female [%]</b>		100.0	0.0	100.0
<b>HBI (Ø, range)</b>			4 (3-5)	
<b>Mayo c.s. (Ø, range)</b>				1 (0-1)
<b>Therapy [%]</b>	<i>Aminosalicylates</i>		0.0	66.7
	<i>Steroids</i>		0.0	0.0
	<i>Immunosuppressants</i>		0.0	0.0
	<i>Anti-TNF antibodies</i>		50.0	100.0
	<i>Vedolizumab</i>		0.0	0.0
	<i>Ustekinumab</i>		50.0	0.0
<b>Disease localization [%]</b>		L1: 0.0	E1: 33.3	
		L2: 0.0	E2: 33.3	
		L3: 50.0	E3: 33.3	
		L4: 0.0		
		L4+ <sup>1</sup> : 50.0		

<sup>1</sup> Concomitant lower and upper gastrointestinal disease